The scale of the analysis lends the observation considerable weight. Researchers examined the prevalence of four neurodivergent conditions, namely ADHD, autism, dyslexia and dyspraxia, among approximately 4.2 million individuals newly diagnosed with type 2 diabetes in the TriNetX US collaborative network between March 2006 and March 2026. To account for demographic differences that might otherwise distort the comparison, each ten-year age band of people with diabetes was matched by age, year of birth, sex, ethnicity and race to individuals without the condition, drawn from a pool of 17.1 million. In total, 3.4 million matched pairs aged younger than eighty years entered the final analysis. This matching strategy is important because neurodivergent conditions are not distributed evenly across the population, and differences in sex, ethnicity or birth cohort could easily masquerade as a diabetes link if left unadjusted.

The headline numbers are most dramatic at the youngest ages. Among people diagnosed with type 2 diabetes before their twentieth birthday, ADHD reached a prevalence of 14.4 percent, compared with 6.9 percent among matched individuals of similar age without diabetes, a difference of just over twofold. Autism showed an even steeper gap, at 5.72 percent versus 1.79 percent, meaning the condition was more than three times as prevalent in the young diabetes group. Dyslexia and dyspraxia were also more common among younger people overall, and across all ages people with type 2 diabetes were roughly twice as likely to have dyslexia as those without, although this difference did not appear to follow any obvious pattern with age at diagnosis. Taken together, the data suggest that as many as one in seven young people with early-onset type 2 diabetes may also be living with ADHD, and roughly one in twenty with autism.

Age emerged as a critical variable in the analysis. Across both groups, the prevalence of neurodiversity was highest at younger ages and declined rapidly with increasing age, becoming extremely low beyond the age of forty. The gap between those with and without diabetes narrowed as age at diagnosis rose. ADHD, for example, was around 1.4 times more prevalent among people diagnosed with type 2 diabetes at seventy to seventy-nine years, at 0.25 percent versus 0.18 percent, compared with the more than twofold difference seen in the under-twenties. Autism followed the same trajectory, being 1.24 times higher in the oldest diagnostic group, although prevalence was so low in that age band, less than 0.01 percent with or without diabetes, that the comparison is difficult to interpret. The concentration of the association in youth is precisely what makes the findings clinically consequential, since early-onset diabetes is the fastest-growing and most vulnerable segment of the type 2 diabetes population.

The clinical stakes are considerable. Early-onset type 2 diabetes is associated with poorer health outcomes than later-onset disease, partly because a diagnosis at a younger age means a longer lifetime exposure to elevated blood glucose and its vascular consequences, raising the risk of serious complications and early death. Managing the condition demands sustained engagement with healthcare services, careful self-monitoring, medication adherence and lifestyle modification, all of which can be complicated by stigma and the competing demands of early adulthood, such as education, employment and establishing independence. For neurodivergent individuals, these demands can be compounded further. Busy clinics, unfamiliar environments, sensory pressures and communication barriers may make routine diabetes care genuinely difficult to navigate, potentially widening existing inequalities in outcomes.

Lead author Dr Jonathan Goldney, of the University of Leicester Diabetes Research Centre and the NIHR Biomedical Research Centre in Leicester, argued that health services are not currently equipped for this overlap. Health systems, he said, are failing to fully meet the needs of people living with both early-onset type 2 diabetes and neurodiversity, both of which are linked to poorer health outcomes. He noted that neurodivergent people and those with early-onset type 2 diabetes are likely to face unique challenges when navigating busy healthcare environments, communicating with healthcare professionals, and managing their diabetes. In his view, providing healthcare for type 2 diabetes in a way that suits neurodivergent individuals is critical to making care more accessible for everyone, particularly as diagnoses are increasingly being made earlier in life. The authors emphasise that the point is not that most neurodivergent people will develop diabetes, but that services for early-onset disease should be planned with neurodiversity in mind.

Why might neurodivergent conditions and early-onset type 2 diabetes travel together? The authors speculate that several mechanisms could contribute. Lower levels of physical activity, difficulties with sleep, the metabolic effects of certain medications, higher rates of mental health conditions and barriers to accessing healthcare could each plausibly raise cardiometabolic risk over time. Factors operating earlier in life may also matter. Maternal diabetes during pregnancy has previously been associated with altered neurodevelopmental outcomes in children as well as with later cardiometabolic risk, suggesting that shared developmental or genetic pathways could underlie part of the association. Shared genetic architecture between neurodevelopmental conditions and metabolic traits is an active area of research, and the present study was not designed to distinguish between behavioural, environmental, iatrogenic and biological explanations. Disentangling these threads is precisely what the authors say future work should address.

The observational design imposes important caveats. A study of this kind can identify associations but cannot establish cause and effect, and the influence of factors that were not measured cannot be ruled out. The analysis relied on anonymised hospital records, which may be prone to coding errors and were not collected specifically for research purposes. There is also a detection issue: people with neurodivergent conditions tend to have more frequent contact with healthcare professionals, which could increase the opportunities for a type 2 diabetes diagnosis to be made and recorded, inflating the apparent association. Furthermore, because the study only included people who had attended hospital, the sample may not be fully representative of the wider population and could exclude healthier individuals, a limitation that may have affected the prevalence estimates particularly among younger people without diabetes, where the comparison figures were very low.

Despite these limitations, the sheer size of the matched cohort makes the central signal difficult to dismiss, and the authors are clear about what should happen next. Future studies, they say, should explore the factors underlying the association between neurodivergent conditions and type 2 diabetes, and should test whether diabetes care that explicitly takes neurodiversity into account can improve health outcomes. Practical implications could include longer or more flexible appointments, adapted communication styles, sensory-considered clinic environments and closer collaboration between diabetes teams and neurodevelopmental services. The authors declare no conflicts of interest. As early-onset type 2 diabetes continues to climb among adolescents and young adults, the study suggests that recognising and accommodating neurodiversity will be an essential part of building diabetes services that work for the patients who need them most.

Subject of Research: The association between neurodivergent conditions and early-onset type 2 diabetes in a large matched cohort study

Article Title: High prevalence of neurodiversity among young people diagnosed with type 2 diabetes, suggests study of over 6 million people

Article References: High prevalence of neurodiversity among young people diagnosed with type 2 diabetes, suggests study of over 6 million people. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: type 2 diabetes, neurodiversity, ADHD, autism, early-onset diabetes, EASD, TriNetX, dyslexia, dyspraxia, health services, observational study, cardiometabolic risk

The scale of the investigation is what sets it apart. The research team, led by Zihan Dong of Karolinska Institutet in Sweden together with an international consortium spanning more than thirty institutions, identified 1,929,027 adults who received a first recorded diagnosis of type 2 diabetes between 2010 and 2020. Of these, roughly 47 percent were male. Because the study drew on national health registries, insurance claims databases, and prescription records rather than self-report, the researchers could capture ADHD diagnoses and medication dispensations with a degree of completeness that smaller single-country studies cannot match. Each national dataset was analysed under a standardized analytical protocol before the results were combined, a design choice that minimizes the methodological heterogeneity that has plagued earlier cross-study comparisons.

The headline result is stark: adults with type 2 diabetes and co-occurring ADHD had a hazard ratio of 2.42 for all-cause mortality after their diabetes diagnosis, with a 95 percent confidence interval of 1.72 to 3.41. In practical terms, even after accounting for the uncertainty inherent in observational data, the death rate among these patients was more than double that of their diabetes-only counterparts. Crucially, the association held after the researchers adjusted for sex, age, calendar year at diabetes diagnosis, psychiatric history, use of other psychotropic medications, and use of cardiometabolic drugs—the standard arsenal of confounders that critics of pharmacoepidemiology studies typically raise. The consistency of the signal across seven healthcare systems with different diagnostic cultures, treatment guidelines, and record-keeping infrastructures strengthens the case that the finding reflects a genuine clinical phenomenon rather than an artifact of any single country’s data.

Perhaps more surprising is what the study did not find. ADHD was not consistently associated with major adverse cardiac events—a composite outcome encompassing acute myocardial infarction, stroke, and cardiovascular disease-related death. The pooled hazard ratio for MACE was 1.04, with a confidence interval of 0.81 to 1.35, meaning the data cannot distinguish the true effect from no effect at all. This dissociation between mortality and cardiac events is scientifically intriguing. It suggests that the excess deaths among diabetes patients with ADHD may not be driven primarily by the classical cardiovascular pathway that dominates outcomes research in type 2 diabetes. Alternative explanations could include non-cardiac causes of death, difficulties with diabetes self-management, higher rates of psychiatric comorbidity, medication non-adherence, or lifestyle factors that are harder to capture in registry data. The authors note that the mortality signal was robust while the cardiac one was not, a pattern that warrants deeper investigation into the specific causes of death in this population.

The study also examined a second, clinically urgent question: among adults who have both type 2 diabetes and ADHD, does taking ADHD medication change cardiovascular risk? Here the answer was conditional and age-dependent. Overall, ADHD medication use was not associated with elevated MACE risk across the full cohort. But when the researchers stratified by age at diabetes onset, a clear signal emerged: among patients diagnosed with type 2 diabetes before age 45—so-called early-onset type 2 diabetes—ADHD medication use was associated with a hazard ratio of 1.58 for major adverse cardiac events, with a confidence interval of 1.18 to 2.10. That interval excludes the null value, indicating a statistically reliable elevation in risk within this younger subgroup.

The age stratification matters because early-onset type 2 diabetes is itself an aggressive disease. Patients diagnosed in early adulthood accumulate longer lifetime exposure to hyperglycemia and typically face higher cumulative risks of retinopathy, nephropathy, and cardiovascular complications than those diagnosed later in life. Layering stimulant and non-stimulant ADHD medications onto an already vulnerable metabolic profile may compound that risk. Stimulant medications such as methylphenidate and amphetamine derivatives act on the sympathetic nervous system, raising heart rate and blood pressure—effects that are generally well tolerated in healthy adults but potentially consequential in patients with insulin resistance, dyslipidemia, and emerging vascular disease. The study’s time-varying exposure design, which allowed medication status to change over the follow-up period rather than being fixed at baseline, lends additional credibility to this subgroup finding.

Methodologically, the researchers employed cause-specific Cox proportional hazards models, the workhorse of survival analysis, to estimate hazard ratios with 95 percent confidence intervals for each country separately. These country-specific estimates were then pooled using random-effects meta-analysis, a technique that assumes the true effect may vary across populations and quantifies that variability rather than pretending it does not exist. Treating both ADHD status and medication use as time-varying exposures was a deliberate safeguard against immortal time bias, a subtle distortion that arises when researchers classify patients by a status they could only achieve after surviving a certain period. The adherence to the STROBE reporting guidelines for observational epidemiology further signals the team’s attention to transparency and reproducibility.

The study was supported by the European Union Horizon 2020 Research and Innovation Programme, along with national funders including the Australian National Health and Medical Research Council, and the funders had no role in the design, analysis, or publication decisions. The authors declared a range of competing interests typical of a large psychiatric-pharmacoepidemiology collaboration, including speaker fees and research funding from pharmaceutical companies for several senior investigators, all reported as outside the submitted work. The article is published open access under a Creative Commons Attribution license, and the team has shared supplementary materials detailing the country-specific analyses.

For clinicians, the message is twofold. First, a diagnosis of ADHD in an adult with type 2 diabetes should prompt intensified monitoring and integrated somatic-psychiatric care, because the co-occurrence marks a population at substantially elevated risk of dying. Adults with ADHD are, on average, diagnosed with type 2 diabetes at younger ages and may experience greater difficulty adhering to complex medication regimens, dietary recommendations, and glucose monitoring routines—mechanisms the study’s authors flag as plausible contributors to the mortality gap. Second, the decision to prescribe ADHD medication to a patient with early-onset type 2 diabetes deserves careful individualized consideration, weighing the demonstrated benefits of treatment on function and safety against a possible cardiovascular signal in this vulnerable group. The researchers emphasize that their findings suggest a potential need for integrated care models and careful medication stewardship, particularly for younger-onset diabetes, rather than any blanket restriction on ADHD treatment.

The broader significance of the work lies in its demonstration that psychiatric comorbidity is not a peripheral concern in metabolic disease. As ADHD diagnoses in adults continue to rise and as type 2 diabetes increasingly affects younger populations, the overlap between the two conditions will grow. Studies of this scale, harnessing the combined statistical power of seven national data systems, provide the evidentiary foundation that single-country analyses cannot. What remains to be established is the mechanism: whether the doubled mortality reflects biological interactions, behavioral pathways, healthcare access disparities, or some combination of all three. Answering that question will determine whether the intervention that matters most is cardiological, psychiatric, or structural—and for now, the study’s authors argue, the safest bet is closer collaboration between the specialists who treat the brain and those who treat the blood sugar.

Subject of Research: The association of ADHD and ADHD medication use with major adverse cardiac events and mortality in adults with type 2 diabetes

Article Title: Major adverse cardiac events and mortality associated with ADHD and its treatment in adults with type 2 diabetes: a multi-national cohort study

Article References: Dong, Z., Zhou, Y., Yao, H., Liu, S., Astrup, A., Engeland, A., Gao, L., Gillies, M. B., Lunde, A., Zhang-James, Y., Araki, M., Brikell, I., Butwicka, A., Dalsgaard, S., D’Onofrio, B. M., Faraone, S. V., Gudbjornsdottir, S., Haavik, J., Kuja-Halkola, R., … Du Rietz, E. (2026). Major adverse cardiac events and mortality associated with ADHD and its treatment in adults with type 2 diabetes: a multi-national cohort study. BMC Medicine, 24(1), Article 527. https://doi.org/10.1186/s12916-026-05246-4

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05246-4

Keywords: ADHD, type 2 diabetes, major adverse cardiac events, mortality, ADHD medication, cardiovascular risk, cohort study, pharmacoepidemiology, early-onset diabetes, multinational study, psychiatric comorbidity, BMC Medicine

Early onset type 2 diabetes, abbreviated EOT2D, is increasingly recognised by clinicians as a distinct and particularly aggressive clinical phenotype. Because it strikes in the third and fourth decades of life, the disease has decades longer to inflict damage on blood vessels, nerves, kidneys and the heart. People diagnosed young experience more rapid deterioration in blood sugar control, develop complications earlier, and face a lower life expectancy than those whose type 2 diabetes appears later in life. As rates of obesity rise across the globe, the number of young adults affected is climbing steeply, making the search for potent, disease-modifying interventions an urgent priority for health systems worldwide.

The biological rationale behind the trial, known as RESET for Remission, rests on the complementary effects of dietary energy restriction and exercise. Low energy diets have previously been shown to drive glucose levels below the diagnostic threshold for type 2 diabetes without the need for medication, a state defined as remission. Adding structured exercise may deliver synergistic advantages: greater cardiorespiratory fitness, preservation of muscle mass during rapid weight loss, enhanced cardiac function, and reduced insulin resistance. The researchers reasoned that a condition as aggressive as early onset type 2 diabetes merits an intervention powerful enough to arrest its swift evolution, and they designed the study to test whether combining the two approaches would outperform usual care.

The trial was a randomised, open-label, blinded endpoint efficacy study conducted across three centres in England and Canada, affiliated with the University of Leicester, McGill University in Montreal, and the University of Alberta in Edmonton. It enrolled adults aged 18 to 45 with early onset type 2 diabetes and obesity who were not taking insulin therapy. Between September 24, 2021 and June 6, 2025, a total of 96 participants were randomised, 40 in the United Kingdom and 56 in Canada. The intervention group comprised 24 women and 26 men, while the control group had 21 women and 25 men. The mean age of participants was 38 years and the mean body mass index was 35.2 kilograms per square metre. Notably, 86 participants, or 90 percent, attended final assessments, a retention rate that strengthens confidence in the findings.

The intervention itself was demanding but carefully structured. Participants stopped all glucose-lowering and blood pressure-lowering medication, in the absence of albuminuria, as they began an 800 to 900 kilocalorie per day diet providing 30 percent of energy from protein, 50 percent from carbohydrate and 20 percent from fat. They were encouraged to drink at least two litres of calorie-free fluid daily and were given a fibre-based laxative to use as required. The first two weeks consisted of total meal replacement using Optifast. From weeks 3 to 12, the same caloric intake continued with more variety, using Optifast in the United Kingdom and ProtiDiet in Canada, alongside one food-based meal per day supplying 60 to 90 grams of protein from all sources combined, one portion of fruit and two portions of non-starchy vegetables.

Exercise ran in parallel with the dietary phase. During weeks 1 to 12, participants completed twice-weekly supervised sessions covering both aerobic and resistance training, plus one weekly independent exercise session. From weeks 13 to 24, they transitioned to a weight-maintenance diet while continuing independent exercise. The primary outcome was remission at 24 weeks, defined as a glycated haemoglobin level below 6.5 percent, or 48 millimoles per mole, together with the absence of glucose-lowering medication for at least 12 weeks. The primary efficacy and harms analysis included all randomised individuals, with a conservative assumption that missing data meant no remission. Secondary endpoints captured cardiorespiratory fitness, body composition and cardiac structure.

The results were striking across multiple dimensions. Intervention participants, who averaged 100.7 kilograms at baseline, lost a mean of 8.4 kilograms by week 24, reaching an average weight of 92.3 kilograms. Control participants, who averaged 103.2 kilograms at the start, lost only 1.2 kilograms, ending at a mean of 102.0 kilograms. After statistical adjustment, the analysis showed that intervention participants lost 7.5 kilograms more than controls, including 6.6 additional kilograms of fat mass. Critically, the trial demonstrated that fat-free mass and muscle preservation are achievable even during rapid weight loss, a finding the authors attribute to the resistance training component that deliberately targeted muscle during the intensive dietary phase.

Safety data were reassuring. Remission was achieved without any severe adverse events. Most participants in the intervention group, 43 of 50, experienced at least one adverse event, compared with 6 of 46 in the control group, but these were mainly the familiar early effects of very low energy diets, such as constipation, headache, dizziness and fatigue, all of which resolved. This profile mirrors what has been reported in previous meal replacement trials and suggests that, under appropriate supervision, the intervention is tolerable for the majority of young adults willing to undertake it.

The authors emphasised the breadth of the benefits beyond blood sugar control. In their summary of the RESET for Remission findings, they report that combining structured aerobic and resistance exercise with a low-calorie diet produced high remission rates, induced fat loss while preserving muscle mass, improved muscle quality and function, enhanced cardiovascular health, and led to meaningful improvements in patient-reported outcomes. They noted that their remission rates sit at the upper end of those previously reported in the literature for trials of similar duration, and that this is the first time such effects have been demonstrated in a multi-ethnic population with early onset type 2 diabetes through a combined low energy diet and structured exercise intervention.

The researchers are candid about the challenges that remain. All weight loss programmes, including low energy diets used for type 2 diabetes remission, are typically followed by a period of partial or full weight regain for most people. Because weight loss driven by lower energy intake alone reduces both fat and fat-free mass, and there is some evidence that weight regain may preferentially restore fat over fat-free mass, there is a long-term risk of net muscle loss and increased sarcopenia. Preserving muscle during remission-oriented weight loss, they argue, may have important implications for long-term metabolic health, physical function and disease trajectory, though this requires confirmation in longer-term studies. They also highlight that their approach may be particularly valuable for those seeking or with potential for pregnancy, a group in which medication options are limited. As the global prevalence of early onset type 2 diabetes continues to rise, the team concludes that the findings present an opportunity to re-evaluate treatment paradigms and support scalable implementation of integrated dietary and exercise interventions, pending further evaluation in real-world settings.

Subject of Research: Remission of early onset type 2 diabetes through a combined low energy diet and structured exercise intervention

Article Title: Study shows low energy diet combined with structured exercise reverses early onset type 2 diabetes in half of participants

Article References: Study shows low energy diet combined with structured exercise reverses early onset type 2 diabetes in half of participants. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: type 2 diabetes, diabetes remission, low energy diet, structured exercise, early onset diabetes, randomised controlled trial, weight loss, resistance training, McGill University, University of Leicester, EASD, The Lancet Regional Health Americas